Literature DB >> 17592554

Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells.

Marcela V Karpuj1, Kurt Giles, Sagit Gelibter-Niv, Michael R Scott, Vishwanath R Lingappa, Francis C Szoka, David Peretz, Wilfred Denetclaw, Stanley B Prusiner.   

Abstract

Prions are composed solely of the disease-causing prion protein (PrPSc) that is formed from the cellular isoform PrPC by a posttranslational process. Here we report that short phosphorothioate DNA (PS-DNA) oligonucleotides diminished the levels of both PrPC and PrPSc in prion-infected neuroblastoma (ScN2a) cells. The effect of PS-DNA on PrP levels was independent of the nucleotide sequence. The effective concentration (EC50) of PS-DNA required to achieve half-maximal diminution of PrPSc was approximately 70 nM, whereas the EC50 of PS-DNA for PrPC was more than 50-fold greater. This finding indicated that diminished levels of PrPSc after exposure to PS-DNA are unlikely to be due to decreased PrPC levels. Bioassays in transgenic mice demonstrated a substantial diminution in the prion infectivity after ScN2a cells were exposed to PS-DNAs. Whether PS-DNA will be useful in the treatment of prion disease in people or livestock remains to be established.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592554      PMCID: PMC1892763          DOI: 10.2119/2006–00073.Karpuj

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  52 in total

1.  Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein.

Authors:  Y Yedidia; L Horonchik; S Tzaban; A Yanai; A Taraboulos
Journal:  EMBO J       Date:  2001-10-01       Impact factor: 11.598

2.  Postexposure prophylaxis against prion disease with a stimulator of innate immunity.

Authors:  Shneh Sethi; Grayson Lipford; Hermann Wagner; Hans Kretzschmar
Journal:  Lancet       Date:  2002-07-20       Impact factor: 79.321

3.  Conformation of PrP(C) on the cell surface as probed by antibodies.

Authors:  Estelle Leclerc; David Peretz; Haydn Ball; Laura Solforosi; Giuseppe Legname; Jiri Safar; Ana Serban; Stanley B Prusiner; Dennis R Burton; R Anthony Williamson
Journal:  J Mol Biol       Date:  2003-02-14       Impact factor: 5.469

4.  Potent inhibition of scrapie prion replication in cultured cells by bis-acridines.

Authors:  Barnaby C H May; Aaron T Fafarman; Septima B Hong; Michael Rogers; Leslie W Deady; Stanley B Prusiner; Fred E Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

5.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease.

Authors:  Anthony R White; Perry Enever; Mourad Tayebi; Rosey Mushens; Jackie Linehan; Sebastian Brandner; David Anstee; John Collinge; Simon Hawke
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

6.  Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein.

Authors:  G Schmitt-Ulms; G Legname; M A Baldwin; H L Ball; N Bradon; P J Bosque; K L Crossin; G M Edelman; S J DeArmond; F E Cohen; S B Prusiner
Journal:  J Mol Biol       Date:  2001-12-14       Impact factor: 5.469

7.  Prion-protein-specific aptamer reduces PrPSc formation.

Authors:  Daniela Proske; Sabine Gilch; Franziska Wopfner; Hermann M Schätzl; Ernst-L Winnacker; Michael Famulok
Journal:  Chembiochem       Date:  2002-08-02       Impact factor: 3.164

8.  Thioaptamer interactions with prion proteins: sequence-specific and non-specific binding sites.

Authors:  David J King; Jiri G Safar; Giuseppe Legname; Stanley B Prusiner
Journal:  J Mol Biol       Date:  2007-02-09       Impact factor: 5.469

9.  Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model.

Authors:  Steven J Collins; Victoria Lewis; Marcus Brazier; Andrew F Hill; Ashley Fletcher; Colin L Masters
Journal:  Ann Neurol       Date:  2002-10       Impact factor: 10.422

10.  Anti-prion antibodies for prophylaxis following prion exposure in mice.

Authors:  Einar M Sigurdsson; Man-Sun Sy; Ruliang Li; Henrieta Scholtzova; Richard J Kascsak; Regina Kascsak; Richard Carp; Harry C Meeker; Blas Frangione; Thomas Wisniewski
Journal:  Neurosci Lett       Date:  2003-01-23       Impact factor: 3.046

View more
  13 in total

Review 1.  Developing Therapeutics for PrP Prion Diseases.

Authors:  Kurt Giles; Steven H Olson; Stanley B Prusiner
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

2.  Conditional modulation of membrane protein expression in cultured cells mediated by prion protein recognition of short phosphorothioate oligodeoxynucleotides.

Authors:  Marcela Viviana Karpuj; Sagit Gelibter-Niv; Anat Tiran; Angelika Rambold; Jörg Tatzelt; Max Nunziante; Hermann M Schatzl
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

3.  Binding of recombinant but not endogenous prion protein to DNA causes DNA internalization and expression in mammalian cells.

Authors:  Shaoman Yin; Xingjun Fan; Shuiliang Yu; Chaoyang Li; Man-Sun Sy
Journal:  J Biol Chem       Date:  2008-07-11       Impact factor: 5.157

4.  Oligonucleotide modifications enhance probe stability for single cell transcriptome in vivo analysis (TIVA).

Authors:  S B Yeldell; B K Ruble; I J Dmochowski
Journal:  Org Biomol Chem       Date:  2017-12-06       Impact factor: 3.876

Review 5.  Development of Phosphorothioate DNA and DNA Thioaptamers.

Authors:  David E Volk; Ganesh L R Lokesh
Journal:  Biomedicines       Date:  2017-07-13

6.  Antisense oligonucleotides extend survival of prion-infected mice.

Authors:  Gregory J Raymond; Hien Tran Zhao; Brent Race; Lynne D Raymond; Katie Williams; Eric E Swayze; Samantha Graffam; Jason Le; Tyler Caron; Jacquelyn Stathopoulos; Rhonda O'Keefe; Lori L Lubke; Andrew G Reidenbach; Allison Kraus; Stuart L Schreiber; Curt Mazur; Deborah E Cabin; Jeffrey B Carroll; Eric Vallabh Minikel; Holly Kordasiewicz; Byron Caughey; Sonia M Vallabh
Journal:  JCI Insight       Date:  2019-07-30

7.  Intracerebral Infusion of Antisense Oligonucleotides Into Prion-infected Mice.

Authors:  Karah Nazor Friberg; Gene Hung; Ed Wancewicz; Kurt Giles; Chris Black; Sue Freier; Frank Bennett; Stephen J Dearmond; Yevgeniy Freyman; Pierre Lessard; Sina Ghaemmaghami; Stanley B Prusiner
Journal:  Mol Ther Nucleic Acids       Date:  2012-02-07       Impact factor: 10.183

8.  Discovery of a novel, monocationic, small-molecule inhibitor of scrapie prion accumulation in cultured sheep microglia and Rov cells.

Authors:  James B Stanton; David A Schneider; Kelcey D Dinkel; Bethany F Balmer; Timothy V Baszler; Bruce A Mathison; David W Boykin; Arvind Kumar
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

Review 9.  Infectious particles, stress, and induced prion amyloids: a unifying perspective.

Authors:  Laura Manuelidis
Journal:  Virulence       Date:  2013-04-30       Impact factor: 5.882

Review 10.  Unraveling Prion Protein Interactions with Aptamers and Other PrP-Binding Nucleic Acids.

Authors:  Bruno Macedo; Yraima Cordeiro
Journal:  Int J Mol Sci       Date:  2017-05-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.